Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Steven C Pugliese & Todd M Bull. (2016) Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension. Integrated Blood Pressure Control 9, pages 1-7.
Read now
Read now
Peter Norman. (2016) Orphan drug approvals of 2015: Europe and the United States. Expert Opinion on Orphan Drugs 4:5, pages 491-500.
Read now
Read now
Matthias Hoch, Borje Darpo, Tatiana Remenova, Randall Stoltz, Meijian Zhou, Priska Kaufmann, Shirin Bruderer & Jasper Dingemanse. (2015) A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist. Drug Design, Development and Therapy 9, pages 175-185.
Read now
Read now
Nicholas S Hill, Kari Roberts & Ioana Preston. (2015) Pulmonary hypertension trials: how can we do better?. Expert Review of Respiratory Medicine 9:5, pages 551-558.
Read now
Read now
Peter Norman. (2015) Evaluation of US20150011555. An inhaled IP receptor agonist for the treatment of pulmonary arterial hypertension. Expert Opinion on Therapeutic Patents 25:8, pages 939-944.
Read now
Read now
Peter Norman. (2014) Pulmonary arterial hypertension: a rare disease that encourages the development of multiple treatments. Expert Opinion on Orphan Drugs 2:11, pages 1137-1145.
Read now
Read now
Articles from other publishers (19)
Meng Li, Lin Liu, Cong Liu, Zebin Chen, Weibin Li, Xuejuan Li, Xiaopeng Ma & Yumao Zhang. (2023) Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review. Clinical Therapeutics.
Crossref
Crossref
Jie Ren, Chao Pi, Xiuling Cui & Yangjie Wu. (2022)
Divergent C(sp
2
)–H arylation of heterocycles
via
organic photoredox catalysis
. Green Chemistry 24:7, pages 3017-3022.
Crossref
Crossref
Lucas Caruso, Nathalia Fonseca Nadur, Marina Brandão da Fonseca, Larissa de Almeida Peixoto Ferreira, Renata Barbosa Lacerda, Cedric Stephan Graebin & Arthur Eugen Kümmerle. (2022) The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two
(or more) Birds on One Stone. Current Topics in Medicinal Chemistry 22:5, pages 366-394.
Crossref
Crossref
Liang Cao, He Zhao, Rongqing Guan, Huanfeng Jiang, Pierre. H. Dixneuf & Min Zhang. (2021) Practical iridium-catalyzed direct α-arylation of N-heteroarenes with (hetero)arylboronic acids by H2O-mediated H2 evolution. Nature Communications 12:1.
Crossref
Crossref
Georg Hansmann, Katharina Meinel, Mila Bukova, Philippe Chouvarine, Håkan Wåhlander & Martin Koestenberger. (2020) Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. The Journal of Heart and Lung Transplantation 39:7, pages 695-706.
Crossref
Crossref
Ifeoma Oriaku, Amol Patel & Zeenat Safdar. (2020) Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension. Pulmonary Circulation 10:1, pages 1-3.
Crossref
Crossref
Kristin B. Highland, Michael Hull, Janis Pruett, Caitlin Elliott, Yuen Tsang & William Drake. (2019) Baseline history of patients using selexipag for pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease 13, pages 175346661984377.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K. -C. Liu, Sarah J. Fink & Christopher J. O’Donnell. (2017) Synthetic Approaches to the New Drugs Approved During 2015. Journal of Medicinal Chemistry 60:15, pages 6480-6515.
Crossref
Crossref
Peter J. Leary, Suhyun Kang, Todd M. Kolb, Bradley A. Maron, David D. Ralph, Youlan Rao, Ryan J. Tedford & Roham T. Zamanian. (2017) What’s in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. International Journal of Cardiology 240, pages 386-391.
Crossref
Crossref
Martha Kingman, Christine Archer‐Chicko, Mary Bartlett, Joy Beckmann, Robin Hohsfield & Sandra Lombardi. (2017) Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulmonary Circulation 7:3, pages 598-608.
Crossref
Crossref
Changjun YangKelly M. DeMarsJon C. AlexanderMarcelo FeboEduardo Candelario-Jalil. (2017) Sustained Neurological Recovery After Stroke in Aged Rats Treated With a Novel Prostacyclin Analog. Stroke 48:7, pages 1948-1956.
Crossref
Crossref
Christine DiversDavid PlattEdward WangJay LinMelissa Lingohr-SmithStephen C. Mathai. (2017) A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States. Journal of Managed Care & Specialty Pharmacy 23:1, pages 92-104.
Crossref
Crossref
Harrison W. Farber & Wendy Gin-Sing. (2016) Practical considerations for therapies targeting the prostacyclin pathway. European Respiratory Review 25:142, pages 418-430.
Crossref
Crossref
Priska Kaufmann, Hans G. Cruz, Andreas Krause, Ivan Ulč, Atef Halabi & Jasper Dingemanse. (2016) Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. British Journal of Clinical Pharmacology 82:2, pages 369-379.
Crossref
Crossref
Sivasubramanian Ramakrishnan. (2015) Current Concepts in Management of Pulmonary Hypertension: Fighting the Old Demon with Modern Weapons. The Indian Journal of Pediatrics 82:12, pages 1128-1134.
Crossref
Crossref
Lucie H. Clapp & Rijan Gurung. (2015) The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. Prostaglandins & Other Lipid Mediators 120, pages 56-71.
Crossref
Crossref
Ayodeji Adegunsoye, Matthew Levy & Olusegun Oyenuga. (2015) Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. BioMed Research International 2015, pages 1-16.
Crossref
Crossref
Andrea Olschewski, Rita Papp, Chandran Nagaraj & Horst Olschewski. (2014) Ion channels and transporters as therapeutic targets in the pulmonary circulation. Pharmacology & Therapeutics 144:3, pages 349-368.
Crossref
Crossref
Mala Sharma, Sowmya Pinnamaneni, Wilbert S. Aronow, Bartosz Jozwik & William H. Frishman. (2014) Existing Drugs and Agents Under Investigation for Pulmonary Arterial Hypertension. Cardiology in Review 22:6, pages 297-305.
Crossref
Crossref